Efficacy assessment of hCCR8 and/or hCCL1-targeting compounds with genO-hCCR8/hCCL1

‍

What sets our model apart?

The double-humanized genO-hCCR8/hCCL1 mouse model enables translational efficacy testing of hCCR8 and/or hCCL1 antibodies for Treg depletion, compared to single humanized models:

‍

‍

Key features

Physiological regulation and expression pattern of human CCR8 and human CCL1
Functional CCR8/CCL1 signaling axis
Fully functional mouse immune system
Lack of expression of the murine target gene

‍

Efficacy assessment of an anti-hCCR8 monoclonal antibody

Adapted from genOway's poster presented at AACR 2025

‍

Safety assessment of hCCR8 and/or hCCL1 antibodies with genO-BRGSF-HIS

‍

What sets our model apart?

Our CD34⁺ HSC-reconstituted genO-BRGSF-HIS mouse model, which features functional human lymphoid and myeloid compartments, enables translational safety assessment of antibodies targeting hCCR8 and/or hCCL1, thanks to the CCR8 expression in peripheral Tregs.

‍

Key features

Functional human myeloid and lymphoid compartments upon CD34⁺-reconstitution
Dynamic recruitment and activation profile of immune cells into the TME shaped by tumor burden and type
Presence of functional γδ T cells
Reduced number of murine myeloid cells
Long lifespan and stable immune system engraftment enabling assessment of compounds with large therapeutic window
Highly permissive to PDX and CDX engraftment
Resistance to irradiation

‍